Skip to the main content.

Press | ​Accelerating Timelines Vital to Securing Slice of Biosimilars Market, KBI

Picture of Admin Admin Sep 3, 2017 5:10:00 AM

News

Accelerating timelines vital to securing slice of biosimilars market, KBI

By Dan Stanton+, 24-Aug-2016

Accelerated development gives biosimilars an upper hand in gaining market share, CMO KBI Biopharma told delegates in Korea yesterday.

http://www.biopharma-reporter.com/Upstream-Processing/Expediting-timelines-key-to-securing-slice-of-biosimilars-market-KBI
KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate

KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate

KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology Durham,...

Read More
Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company

Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization...

Read More
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer

Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...

Read More